Trials / Terminated
TerminatedNCT02437916
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
Conditions
- Advanced Malignancy
- Advanced Solid Tumors
- Cancer
- Oncology
- Oncology Patients
- Tumors
- Melanoma
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Transitional Cell Carinoma of Bladder
- Colorectal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 228 | AMG 228 will be administered intravenously |
Timeline
- Start date
- 2015-04-21
- Primary completion
- 2016-12-12
- Completion
- 2016-12-12
- First posted
- 2015-05-08
- Last updated
- 2022-11-08
Locations
7 sites across 5 countries: United States, Australia, Belgium, France, Germany
Source: ClinicalTrials.gov record NCT02437916. Inclusion in this directory is not an endorsement.